Premium
Evaluation of the antihistamine effects of olopatadine and levocetirizine during a 24‐h period: A double‐blind, randomized, cross‐over, placebo‐controlled comparison in skin responses induced by histamine iontophoresis
Author(s) -
Takeo Tomohiro,
Kasugai Chikatoshi,
Tanaka Rui,
Ando Takashi,
Ogawa Akina,
Akita Yoichi,
Watanabe Daisuke
Publication year - 2013
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.12326
Subject(s) - levocetirizine , medicine , histamine , antihistamine , placebo , anesthesia , iontophoresis , pharmacology , histamine h1 receptor , dermatology , antagonist , alternative medicine , receptor , pathology , radiology
The antihistamine effects of olopatadine and levocetirizine, in standard‐dose application described in their information (5 mg twice a day for olopatadine; 5 mg once daily for levocetirizine), were examined from 11.5 to 24 h after application. The test was designed in a double‐blind, randomized, cross‐over, placebo‐controlled study of 12 healthy volunteers on histamine‐induced flare and wheal response using an iontophoresis technique. The suppressive effect of olopatadine on the wheals induced by a 0.1‐mA histamine iontophoresis lasted for 24 h after dosing. Both drugs inhibited flare induced by histamine iontophoresis almost completely until 24 h after the first administration. Suppression of the 0.2‐mA‐induced wheal response by levocetirizine, taken once daily, decreased with time, although 0.1‐mA‐induced flare was almost completely suppressed by the drug. Olopatadine completely suppressed even the wheal response induced by a 0.2‐ mA histamine iontophoresis. Compared with the placebo, the two drugs significantly suppressed the subjective itching assessed by visual analog scale at all intervals. There were no significant differences in subjective drowsiness and objective cognitive function between drug‐ and placebo‐treated subjects. These results demonstrate that olopatadine seems to be more potent than levocetirizine when administrated in a standard dose. In conclusion, mild to moderate urticaria could be controlled by standard application as described in their information. On the other hand, severe urticaria could be managed by a standard application of olopatadine, but levocetirizine may need an additional dose to control severe urticaria.